Results 21 to 30 of about 79,249 (245)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

Clinical and Translational Science, 2022
Curcumin inhibits UDP‐glucuronyltransferases, a primary metabolic pathway for cancer chemotherapeutic agents like irinotecan. Concurrent administration of both agents may exacerbate irinotecan toxicity.
Olumide B. Gbolahan, Bert H. O’Neil, Autumn J. McRee, Hanna K. Sanoff, John K. Fallon, Philip C. Smith, Anastasia Ivanova, Dominic T. Moore, Julie Dumond, Gary N. Asher   +9 more
doaj   +1 more source

Triplet Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Patients with Recurrent or Refractory Non-small Cell Lung Cancer [PDF]

, 2010
We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively.
Fujimoto, Nobukazu, Fujiwara, Yoshiro, Kiura, Katsuyuki, Tabata, Masahiro, Takigawa, Nagio, Tanimoto, Mitsune, Toyooka, Shinichi, Ueoka, Hiroshi, Umemura, Shigeki   +8 more
core   +1 more source

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]

, 2020
Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David, Barkauskas, Donald A, Gatalica, Zoran, Kurzrock, Razelle, Nikanjam, Mina, Swensen, Jeff   +5 more
core   +2 more sources

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]

, 2013
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO, CARUSO, DAVIDE, EVANGELISTA, SALVATORE, Foteini Vakiarou, G. Rinaldi, L. Bianchi, Lo Russo, Giuseppe, PAPA, ANSELMO, Perrone-congedi, Francesca, PRETE, ALESSANDRA ANNA, ROSSI, Luigi, SPINELLI, GIAN PAOLO, Stati, Valeria, TOMAO, SILVERIO, VERRICO, MONICA, ZORATTO, federica   +15 more
core   +1 more source

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

BMC Cancer, 2018
Background The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan.
Diego Tosi, Esther Pérez-Gracia, Salima Atis, Nadia Vié, Eve Combès, Mélissa Gabanou, Christel Larbouret, Marta Jarlier, Caroline Mollevi, Adeline Torro, Maguy Del Rio, Pierre Martineau, Céline Gongora   +12 more
doaj   +1 more source

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer

Oncology and Therapy, 2023
Introduction Liposomal irinotecan promotes controlled sustained release of irinotecan (CPT-11), therefore, we hypothesize that the therapeutic index (quantitative measurement of the relative efficacy/safety ratio of a drug) will be higher for liposomal ...
Sandrine Barbier, Benjamin Beaufils, Ricardo de Miguel, Melissa Reyre, Yannick Le Meitour, Andreanne Lortie, Marc Hillairet de Boisferon, Sophie Chaumeron, Anne Espirito, Lina Fossati, Pauline Lagarde, Stephan Klinz, Arunthathi Thiagalingam, Stéphane Lezmi, Florence Meyer-Losic   +14 more
doaj   +1 more source

Characterization of mucin 2 expression in colorectal cancer with and without chemotherapies, in vivo and in vitro study

Journal of Umm Al-Qura University for Medical Science, 2021
Background: Colorectal cancer (CRC) is the third and second most prevalent cancer affecting males and females, respectively. 5-fluorouracil (5-FU) and irinotecan are the main chemotherapies for CRC.
Hussain Almasmoum
doaj   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source

Synthetic Lethality of Chk1 Inhibition Combined with p53 and/or p21 Loss During a DNA Damage Response in Normal and Tumor Cells [PDF]

, 2013
Cell cycle checkpoints ensure genome integrity and are frequently compromised in human cancers. A therapeutic strategy being explored takes advantage of checkpoint defects in p53-deficient tumors in order to sensitize them to DNA-damaging agents by ...
A Besson, A Eastman, A Goga, A Goloudina, A Z Munir, AA Levesque, AA Levesque, AJ Fikaris, AN Tse, AT Ferguson, B Xu, C Tapia, CJ Sherr, CS Sorensen, CX Ma, EA Kohn, EA Kohn, F Bunz, FI Raynaud, H Piwnica-Worms, H Zhao, I Hassepass, J Bartkova, J Falck, K Shimuta, L S White, LL Parker, MH Lam, MV Cespedes, O Gilad, O Wang, OA Sedelnikova, PM Fracasso, R Di Micco, R Rodriguez, RP Perez, RT Bunch, S Origanti, S-r Cai, SD Zabludoff, T Abbas, T Waldman, WR Taylor, Y Luo   +43 more
core   +2 more sources